

**A CONCISE STRATEGY TOWARDS (–)-POCHONICINE
STEREoisomers AND SYNTHESIS OF NOVEL
HOMOAZANUCLEOSIDES**

RAHUL VILAS SALUNKE



**DEPARTMENT OF CHEMISTRY
INDIAN INSTITUTE OF TECHNOLOGY DELHI
JANUARY 2019**

©Indian Institute of Technology Delhi (IITD), New Delhi, 2019

**A CONCISE STRATEGY TOWARDS (-)-POCHONICINE
STEREoisomers AND SYNTHESIS OF NOVEL
HOMOAZANUCLEOSIDES**

by

RAHUL VILAS SALUNKE
DEPARTMENT OF CHEMISTRY

Submitted

In fulfillment of the requirements of the degree of DOCTOR OF PHILOSOPHY

to the



INDIAN INSTITUTE OF TECHNOLOGY DELHI

JANUARY 2019

*This thesis is dedicated to my wife **Kirti**, my beloved daughter **Ishita***

*And my parents **Mr. Vilas** and **Mrs. Sangita***

CERTIFICATE

This is to certify that thesis entitled “**A Concise Strategy towards (-)-Pochonicine Stereoisomers and Synthesis of Novel Homoazanucleosides**”, being submitted by **RAHUL VILAS SALUNKE** to Indian Institute of Technology Delhi, for the award of the degree of **Doctor of Philosophy**, is a record of bonafide research work carried out by him. Mr Rahul Vilas Salunke has worked under my supervision and guidance and has fulfilled all the requirements for the submission of a Ph.D. thesis, which to my knowledge has reached the requisite standard and is worthy of consideration for the award of Ph.D. degree.

The work embodied in this thesis has not been submitted, in part or full, to other University or Institute for the award of any degree or diploma.

Prof. N. G. Ramesh
Thesis Supervisor
Professor
Department of Chemistry
Indian Institute of Technology Delhi
Hauz Khas, New Delhi-110016, INDIA

ACKNOWLEDGEMENTS

*Firstly, I would like to express my sincere gratitude to my advisor **Prof. N. G. Ramesh** for the continuous support of my Ph.D study and related research, for his patience, motivation, and immense knowledge. His guidance helped me in all the time of research and writing of this thesis. I could not have imagined having a better advisor and mentor for my Ph.D study.*

Besides my advisor, I would like to thank Prof. Nalin Pant for his valuable guidance and interest in my research. I am also grateful Prof. P. S. Pandey, Prof. Shivajirao L. Gholap and to my thesis committee Prof. N. D. Kurur, Prof. Veena Kaul for their insightful comments and encouragement.

My sincere thanks also goes Prof. Ravi Shankar, head of the department for providing departmental facilities.

I would like to thank my seniors late Dr. Vipin Kumar, Dr. M. Ganesan, Dr. Nagarajan, without their pioneering work work I may not have been able to achieve objectives of research.

I thank my fellow labmates Vimal, Venkatesan, Umesh, Abhishek, Pawan, Arup Roy, Naveen, Rahul Soni for their help in carrying out my research work as well as for all the fun we have had during my stay. I especially like to thank Vimal for his help in everything. I also thank Dr. Satish Kannan for his help. I am very much grateful to Mr. Rituraj Mishra for his help.

IIT Delhi for providing institute facilities. I am thankful to Mr. Keshav, Mr. Alok of the NMR lab, Mr. Virender of glass blowing section and all the members of instrument lab and chemistry office. CSIR New Delhi for scholarship.

I deeply thank my family: my parents Sangita and Vilas Salunke my brother Vishal and sister Pooja for supporting me throughout my life. I would like to thank Dr. Santosh Salunke, Dr. Vijay Kasture and Dr. Nitin Kunjir for inspiring and guiding me.

Finally, I thank with love to Kirti and Ishita, my wife and daughter. Understanding me best. Her presence has always been a really great consolation and support to me. We could not spend more time together however, my heart has been and always will be with her for all time.

Finally, my thanks go to all the people who have supported me to complete the research work directly or indirectly.

Rahul Vilas Salunke

ABSTRACT

The thesis titled “**A Concise Strategy towards (–)-Pochonicine Stereoisomers and Synthesis of Novel Homoazanucleosides**” presents the the work carried out on the synthesis of six stereoisomers of (–)-pochonicine, indolizidine alkaloids, novel tricyclic azasugars and homoazanucleosides from a single starting tri-*O*-benzyl-D-glucal. Enzyme inhibition studies against five commercially available glycosidase were also discussed.

Chapter I describes the synthesis of stereoisomers of (–)-pochonicine a novel pyrrolizidine alkaloid, indolizidine alkaloids and tricyclic azasugars. We have reported a concise synthesis of six stereoisomers of (–)-pochonicine through a one-pot *N*-detosylative intramolecular epoxide opening as a key step. Enroute towards (–)-pochonicine stereoisomers we have also synthesized some novel indolizidine alkaloids through a ring expansion reaction. Novel tricyclic alkaloids were also synthesized. Glycosidase inhibition demonstrated (–)-pochonicine stereoisomers are good inhibitors of β -glucosidase and β -*N*-GLcNAcase, however indolizidine alkaloids showed inhibition only against β -glucosidase.

Chapter II describes the synthesis of novel homoazanucleosides and peptidyl homoazanucleosides, hybrid molecules containing three biologically important moieties namely amino acid, azasugar and nucleobase from common starting material tri-*O*-benzyl-D-glucal. In this process, we have also demonstrated the pluri-potency of polyhydroxypyrrolidine synthesized previously in our lab. Glycosidase inhibition studies revealed that all the homoazanucleosides having free amino group did not show any inhibitory activity. However their acetamido derivatives were found to be sub-millimolar inhibitors of β -*N*-acetylglucosaminidase.

सार

थीसिस "(-) की ओर एक संक्षिप्त रणनीति (-)-पोकोनिसिन स्टीरियोआयसोमर्स और उपन्यास होमो-अज़ान्यूक्लिओसाइड्स का संश्लेषण" - (-) के छह स्टीरियोआयसोमर्स के संश्लेषण पर किए गए काम को प्रस्तुत करता है। (-) पोकोनिसिन, इंडोलिज़िडीन एल्कलॉइड्स, नया ट्राइसाइक्लिक अज़ाशुगर और होमो-अज़ान्यूक्लिओसाइड्स ट्राई-ओ-बेंजिल-डी-ग्लुकलसे शुरू करके पांच व्यावसायिक रूप से उपलब्ध ग्लाइकोसिडेज के खिलाफ एंजाइम निषेध अध्ययन पर भी चर्चा की गई।

अध्याय I (-) के स्टीरियोइसोमर्स के संश्लेषण का वर्णन करता है - एक नया पाइरोलिज़िडिन एल्कलॉइड, इंडोलिज़िडिन एल्कलॉइड्स और ट्राइसाइक्लिक अज़ाशुगर। हमने (-) के छह पोकोनिसिन स्टीरियोआयसोमर्स के एक संक्षिप्त संश्लेषण की सूचना दी है - एक महत्वपूर्ण एक- पात्र एन-डिटोसाइलेटिव इंट्रामोलीक्यूलर एपॉक्साइड के माध्यम से से (-)-पोकोनिसिन की ओर अग्रसर - पोकोनिसिन स्टीरियोइसोमर्स हमने एक अंगूठी विस्तार प्रतिक्रिया के माध्यम से कुछ नए इंडोलिज़िडिन एल्कलॉइड को भी संश्लेषित किया है। नए ट्राइसाइक्लिक एल्कलॉइड को भी संश्लेषित किया गया था। ग्लाइकोसिडेस निषेध का प्रदर्शन (-) - पोकोनिसिन स्टीरियोसोमर्स बीटा-ग्लूकोसिडेस और बीटा-एन-एसिटाइलग्लूकोसिडेस के अच्छे अवरोधक हैं, हालांकि इंडोलिज़िडिन एल्कलॉइड केवल बीटा-ग्लूकोसिडेस के खिलाफ निषेध दर्शाते हैं।

अध्याय II में उपन्यास होमोअज़ान्यूक्लिओसाइड्स और पेप्टिडिल होमोअज़ान्यूक्लिओसाइड्स के संश्लेषण का वर्णन किया गया है, जिसमें तीन जैविक रूप से महत्वपूर्ण एकक अर्थात् अमीनो एसिड, अज़ाशुगर और न्यूक्लियोबेस युक्त आम अणु ट्राई-ओ-बेंजिल-डी-ग्लुकल हैं। इस प्रक्रिया में, हमने अपनी प्रयोगशाला में पहले से संश्लेषित पॉलीहाइड्रॉक्सीरिपोलिडिन की प्लुरी-पोर्टेंसी का भी प्रदर्शन किया है। ग्लाइकोसिडेज निषेध अध्ययनों से पता चला है कि मुक्त अमीनो समूह वाले सभी होमोअज़ान्यूक्लिओसाइड्स ने कोई निरोधात्मक गतिविधि नहीं दिखाई थी। हालांकि, उनके एसिटामिडो डेरिवेटिव को बीटा-एन-एसिटाइलग्लूकोसिडेस का उप-मिलिम्मल अवरोधक पाया गया।

TABLE OF CONTENTS

	PAGE
CERTIFICATE	I
ACKNOWLEDGEMENTS	II
ABSTRACT	IV
TABLE OF CONTENTS	V
LIST OF FIGURES	VII
LIST OF TABLES	XIII
GENERAL EXPERIMENTAL CONSIDERATIONS	XIV
COMMON ABBREVIATIONS	XVI
<u>CHAPTER 1: DIVERSITY ORIENTED SYNTHESIS OF (-)-POCHONICINE STEREOISOMERS, INDOLIZIDINE ALKALOIDS, DECAHYDROPYRAZINO-[2,1,6-<i>cd</i>]PYRROLIZINE TRIOLS AND THEIR GLYCOSIDASE INHIBITION STUDIES.</u>	
1.1 Introduction	2
1.2 Objectives	18
1.3 Results and discussion	19
1.4 Conclusions	42
1.5 Experimental	44
1.6 References	113
Copies of NMR spectra of selected compounds	117

CHAPTER 2: SYNTHESIS OF NOVEL HOMOAZANUCLEOSIDES, PEPTIDYL HOMOAZANUCLEOSIDES AND STUDY OF THEIR GLYCOSIDASE INHIBITION ACTIVITIES.

2.1 Introduction	195
2.2 Objectives	216
2.3 Results and discussion	217
2.4 Conclusion	236
2.5 Experimental	237
2.6 References	277
Copies of NMR spectra of selected compounds	284
A BRIEF BIO-DATA OF THE AUTHOR	323

LIST OF FIGURES

CHAPTER I	PAGE
Figure 1.1 Mechanism of hydrolysis of glycosidases by retaining β - <i>N</i> -acetyl-D-hexosaminidases.	3
Figure 1.2 Structures of GH3, GH20 and GH84 β - <i>N</i> -acetyl-D-hexosaminidases.	4
Figure 1.3 Structures of nagstatin and (+)-pochonicine (originally proposed).	5
Figure 1.4 General structures of synthetic β - <i>N</i> -acetyl-D-hexosaminidase inhibitors.	6
Figure 1.5 Structural comparison between pyrrolidine 57 and (-)-pochonicine 35 .	18
Figure 1.6 NOESY correlations in compound 69 .	22
Figure 1.7 NOESY correlations in compound 76 .	24
Figure 1.8 NOE correlations in compound 82 and 83 .	26
Figure 1.9 NOE correlations of compounds 95 , 92 , 97 and 98 .	29
Figure 1.10 NOESY correlations in compound 114 .	34
Figure 1.11 ¹ H-NMR spectrum of compound 62	118
Figure 1.12 ¹³ C-NMR spectrum of compound 62	118
Figure 1.13 ¹ H-NMR spectrum of compound 63	119
Figure 1.14 ¹³ C-NMR spectrum of compound 63	119
Figure 1.15 ¹ H-NMR spectrum of compound 58	120
Figure 1.16 ¹³ C-NMR spectrum of compound 58	120
Figure 1.17 ¹ H-NMR spectrum of compound 59a/59b	121
Figure 1.18 ¹³ C-NMR spectrum of compound 59a/59b	121
Figure 1.19 ¹ H-NMR spectrum of compound 64	122
Figure 1.20 ¹³ C-NMR spectrum of compound 64	122
Figure 1.21 ¹ H-NMR spectrum of compound 65	123
Figure 1.22 ¹³ C-NMR spectrum of compound 65	123
Figure 1.23 ¹ H-NMR spectrum of compound 66	124
Figure 1.24 ¹³ C-NMR spectrum of compound 66	124
Figure 1.25 ¹ H-NMR spectrum of compound 69	125
Figure 1.26 ¹³ C-NMR spectrum of compound 69	125
Figure 1.27 ¹ H-1H-COSY spectrum of compound 69	126
Figure 1.28 HMQC spectrum of compound 69	126
Figure 1.29 ¹ H-1H-NOESY spectrum of compound 69	127
Figure 1.30 ¹ H-NMR spectrum of compound 71	127
Figure 1.31 ¹³ C-NMR spectrum of compound 71	128
Figure 1.32 ¹ H-NMR spectrum of compound 72	129
Figure 1.33 ¹³ C-NMR spectrum of compound 72	129
Figure 1.34 ¹ H-NMR spectrum of compound 74	130
Figure 1.35 ¹³ C-NMR spectrum of compound 74	130
Figure 1.36 ¹ H-NMR spectrum of compound 76	131
Figure 1.37 ¹³ C-NMR spectrum of compound 76	131
Figure 1.38 ¹ H-NMR spectrum of compound 77	132
Figure 1.39 ¹³ C-NMR spectrum of compound 77	132
Figure 1.40 ¹ H-NMR spectrum of compound 78	133
Figure 1.41 ¹³ C-NMR spectrum of compound 78	133
Figure 1.42 ¹ H-NMR spectrum of compound 79	134

Figure 1.43	^{13}C -NMR spectrum of compound 79	134
Figure 1.44	^1H -NMR (D_2O) spectrum of compound 80	135
Figure 1.45	^1H -NMR (CD_3OD) spectrum of compound 80	135
Figure 1.46	^{13}C -NMR spectrum of compound 80	136
Figure 1.47	^1H - ^1H -COSY spectrum of compound 80	136
Figure 1.48	HMQC spectrum of compound 80	137
Figure 1.49	^1H - ^1H -NOESY spectrum of compound 80	137
Figure 1.50	^1H -NMR spectrum of compound 81	138
Figure 1.51	^{13}C -NMR spectrum of compound 81	138
Figure 1.52	^1H -NMR spectrum of compound 82	139
Figure 1.53	^{13}C -NMR spectrum of compound 82	139
Figure 1.54	^1H - ^1H COSY spectrum of compound 82	140
Figure 1.55	^1H - ^1H NOESY spectrum of compound 82	140
Figure 1.56	^1H -NMR spectrum of compound 83	141
Figure 1.57	^{13}C -NMR spectrum of compound 83	141
Figure 1.58	^1H - ^1H -COSY spectrum of compound 83	142
Figure 1.59	^1H - ^1H -NOESY spectrum of compound 83	142
Figure 1.60	^1H -NMR spectrum of compound 84	143
Figure 1.61	^{13}C -NMR spectrum of compound 84	143
Figure 1.62	^1H -NMR spectrum of compound 85	144
Figure 1.63	^{13}C -NMR spectrum of compound 85	144
Figure 1.64	^1H -NMR spectrum of compound 86	145
Figure 1.65	^{13}C -NMR spectrum of compound 86	145
Figure 1.66	^1H -NMR spectrum of compound 87	146
Figure 1.67	^{13}C -NMR spectrum of compound 87	146
Figure 1.68	^1H -NMR spectrum of compound 88	147
Figure 1.69	^{13}C -NMR spectrum of compound 88	147
Figure 1.70	^1H -NMR spectrum of compound 89	148
Figure 1.71	^{13}C -NMR spectrum of compound 89	148
Figure 1.72	^1H -NMR spectrum of compound 90	149
Figure 1.73	^{13}C -NMR spectrum of compound 90	149
Figure 1.74	^1H -NMR spectrum of compound 91	150
Figure 1.75	^{13}C -NMR spectrum of compound 91	150
Figure 1.76	^1H -NMR spectrum of compound 92	151
Figure 1.77	^{13}C -NMR spectrum of compound 92	151
Figure 1.78	^1H - ^1H -COSY spectrum of compound 92	152
Figure 1.79	^1H - ^1H -NOESY spectrum of compound 92	152
Figure 1.80	^1H -NMR spectrum of compound 93	153
Figure 1.81	^{13}C -NMR spectrum of compound 93	153
Figure 1.82	^1H -NMR spectrum of compound 94	154
Figure 1.83	^{13}C -NMR spectrum of compound 94	154
Figure 1.84	^1H -NMR spectrum of compound 95	155
Figure 1.85	^{13}C -NMR spectrum of compound 95	155
Figure 1.86	^1H - ^1H COSY spectrum of compound 95	156
Figure 1.87	^1H - ^1H NOESY spectrum of compound 95	156
Figure 1.88	^1H -NMR spectrum of compound 96	157
Figure 1.89	^{13}C -NMR spectrum of compound 96	157
Figure 1.90	^1H -NMR spectrum of compound 97	158
Figure 1.91	^{13}C -NMR spectrum of compound 97	158
Figure 1.92	^1H - ^1H COSY spectrum of compound 97	159

Figure 1.93	^1H - ^1H NOESY spectrum of compound 97	159
Figure 1.94	^1H -NMR spectrum of compound 98	160
Figure 1.95	^{13}C -NMR spectrum of compound 98	160
Figure 1.96	^1H - ^1H COSY spectrum of compound 98	161
Figure 1.97	^1H - ^1H NOESY spectrum of compound 98	161
Figure 1.98	^1H -NMR spectrum of compound 99	162
Figure 1.99	^{13}C -NMR spectrum of compound 99	162
Figure 1.100	^1H -NMR spectrum of compound 100	163
Figure 1.101	^{13}C -NMR spectrum of compound 100	163
Figure 1.102	^1H -NMR spectrum of compound 101	164
Figure 1.103	^{13}C -NMR spectrum of compound 101	164
Figure 1.104	^1H -NMR spectrum of compound 102	165
Figure 1.105	^{13}C -NMR spectrum of compound 102	165
Figure 1.106	^1H -NMR spectrum of compound 103	166
Figure 1.107	^1H -NMR spectrum of compound 103	166
Figure 1.108	^{13}C -NMR spectrum of compound 103	167
Figure 1.109	^1H -NMR spectrum of compound 104	167
Figure 1.110	^{13}C -NMR spectrum of compound 104	168
Figure 1.111	^1H -NMR spectrum of compound 105	169
Figure 1.112	^{13}C -NMR spectrum of compound 105	169
Figure 1.113	^1H -NMR spectrum of compound 106	170
Figure 1.114	^{13}C -NMR spectrum of compound 106	170
Figure 1.115	^1H -NMR spectrum of compound 108	171
Figure 1.116	^{13}C -NMR spectrum of compound 108	171
Figure 1.117	^1H -NMR spectrum of compound 109	172
Figure 1.118	^{13}C -NMR spectrum of compound 109	172
Figure 1.119	^1H -NMR spectrum of compound 110	173
Figure 1.120	^{13}C -NMR spectrum of compound 110	173
Figure 1.121	^1H -NMR spectrum of compound 111	174
Figure 1.122	^{13}C -NMR spectrum of compound 111	174
Figure 1.123	^1H -NMR spectrum of compound 112a	175
Figure 1.124	^{13}C -NMR spectrum of compound 112a	175
Figure 1.125	^1H -NMR spectrum of compound 112b	176
Figure 1.126	^{13}C -NMR spectrum of compound 112b	176
Figure 1.127	^1H -NMR spectrum of compound 114	177
Figure 1.128	^{13}C -NMR spectrum of compound 114	177
Figure 1.129	^1H - ^1H COSY spectrum of compound 114	178
Figure 1.130	HSQC spectrum of compound 114	178
Figure 1.131	HMBC spectrum of compound 114	179
Figure 1.132	^1H - ^1H NOESY spectrum of compound 114	179
Figure 1.133	^1H -NMR spectrum of compound 115	180
Figure 1.134	^{13}C -NMR spectrum of compound 115	180
Figure 1.135	^1H -NMR spectrum of compound 116	181
Figure 1.136	^{13}C -NMR spectrum of compound 116	181
Figure 1.137	^1H -NMR spectrum of compound 117	182
Figure 1.138	^{13}C -NMR spectrum of compound 117	182
Figure 1.139	^1H -NMR spectrum of compound 118	183
Figure 1.140	^{13}C -NMR spectrum of compound 118	183
Figure 1.141	^1H -NMR spectrum of compound 119	184

Figure 1.142	¹³ C-NMR spectrum of compound 119	184
Figure 1.143	¹ H-NMR spectrum of compound 120	185
Figure 1.144	¹³ C-NMR spectrum of compound 120	185
Figure 1.145	¹ H-NMR spectrum of compound 122	186
Figure 1.146	¹³ C-NMR spectrum of compound 122	186
Figure 1.147	¹ H-NMR spectrum of compound 123	187
Figure 1.148	¹³ C-NMR spectrum of compound 123	187
Figure 1.149	¹ H-NMR spectrum of compound 40	188
Figure 1.150	¹³ C-NMR spectrum of compound 40	188
Figure 1.151	¹ H-NMR spectrum of compound 124	189
Figure 1.152	¹³ C-NMR spectrum of compound 124	189
Figure 1.153	¹ H-NMR spectrum of compound 126	190
Figure 1.154	¹³ C-NMR spectrum of compound 126	190
Figure 1.155	¹ H-NMR spectrum of compound 127	191
Figure 1.156	¹³ C-NMR spectrum of compound 127	191
Figure 1.157	¹ H-NMR spectrum of compound 4	192
Figure 1.158	¹³ C-NMR spectrum of compound 4	192

CHAPTER II

Figure 2.1	Description of nucleosides	195
Figure 2.2	Structures of DNA and RNA	196
Figure 2.3	Natural nucleosides present in DNA and RNA	197
Figure 2.4	Examples of antiviral nucleosides	198
Figure 2.5	Examples of anticancer nucleoside drug molecules	200
Figure 2.6	Synthetic and naturally occurring peptidyl nucleosides	201
Figure 2.7	Various modifications carried out on natural nucleosides	202
Figure 2.8	Examples of carbocyclic nucleosides used as antiviral drugs	203
Figure 2.9	Examples of modified C-nucleosides	204
Figure 2.10	Examples of anti-HCV azanucleosides	205
Figure 2.11	Examples homo azanucleosides	206
Figure 2.12	Comparison of transition state of PNP catalysed phosphorolysis of inosine and Imm-H	207
Figure 2.13	Examples of second and third generation immucillins	208
Figure 2.14	Design of peptidyl homoazanucleoside 99 from polyhydroxypyrrolidine 98	216
Figure 2.15	Single crystal X-ray structure of compound 107.HCl	220
Figure 2.16	¹ H-NMR Comparison between compounds 117 and 120 .	223
Figure 2.17	¹³ C-NMR comparison between compounds 117 and 120 .	223
Figure 2.18	¹³ C-DEPT comparison between compounds 117 and 120 .	224
Figure 2.19	Key HMBC correlations in compounds 136 and 137b	229
Figure 2.20	Single crystal X-ray structure of compound 136	229
Figure 2.21	¹ H-NMR spectrum of compound 101	285
Figure 2.22	¹³ C-NMR spectrum of compound 101	285
Figure 2.23	¹ H-NMR spectrum of compound 102	286
Figure 2.24	¹³ C-NMR spectrum of compound 102	286
Figure 2.25	¹ H-NMR spectrum of compound 103	287
Figure 2.26	¹³ C-NMR spectrum of compound 103	287
Figure 2.27	¹ H-NMR spectrum of compound 105	288
Figure 2.28	¹³ C-NMR spectrum of compound 105	288
Figure 2.29	¹ H-NMR spectrum of compound 106	289

Figure 2.30	^{13}C -NMR spectrum of compound 106	289
Figure 2.31	^1H -NMR spectrum of compound 107	290
Figure 2.32	^{13}C -NMR spectrum of compound 107	290
Figure 2.33	^1H -NMR spectrum of compound 108	291
Figure 2.34	^{13}C -NMR spectrum of compound 108	291
Figure 2.35	^1H -NMR spectrum of compound 110	292
Figure 2.36	^{13}C -NMR spectrum of compound 110	292
Figure 2.37	^1H -NMR spectrum of compound 111	293
Figure 2.38	^{13}C -NMR spectrum of compound 111	293
Figure 2.39	^1H -NMR spectrum of compound 112	294
Figure 2.40	^{13}C -NMR spectrum of compound 112	294
Figure 2.41	^1H -NMR spectrum of compound 113	295
Figure 2.42	^{13}C -NMR spectrum of compound 113	295
Figure 2.43	^1H -NMR spectrum of compound 115	296
Figure 2.44	^{13}C -NMR spectrum of compound 115	296
Figure 2.45	^1H -NMR spectrum of compound 116	297
Figure 2.46	^{13}C -NMR spectrum of compound 116	297
Figure 2.47	^1H -NMR spectrum of compound 117	298
Figure 2.48	^{13}C -NMR spectrum of compound 117	298
Figure 2.49	^1H -NMR spectrum of compound 120	299
Figure 2.50	^{13}C -NMR spectrum of compound 120	299
Figure 2.51	^1H -NMR spectrum of compound 118	300
Figure 2.52	^{13}C -NMR spectrum of compound 118	300
Figure 2.53	^1H -NMR spectrum of compound 124	301
Figure 2.54	^{13}C -NMR spectrum of compound 124	301
Figure 2.55	^1H -NMR spectrum of compound 122	302
Figure 2.56	^{13}C -NMR spectrum of compound 122	302
Figure 2.57	^1H -NMR spectrum of compound 126	303
Figure 2.58	^{13}C -NMR spectrum of compound 126	303
Figure 2.59	^1H -NMR spectrum of compound 127	304
Figure 2.60	^{13}C -NMR spectrum of compound 127	304
Figure 2.61	^1H -NMR spectrum of compound 131	305
Figure 2.62	^{13}C -NMR spectrum of compound 131	305
Figure 2.63	^1H -NMR spectrum of compound 129	306
Figure 2.64	^{13}C -NMR spectrum of compound 129	306
Figure 2.65	^1H -NMR spectrum of compound 133	307
Figure 2.66	^{13}C -NMR spectrum of compound 133	307
Figure 2.67	^1H -NMR spectrum of compound 134	308
Figure 2.68	^{13}C -NMR spectrum of compound 134	308
Figure 2.69	^1H -NMR spectrum of compound 136	309
Figure 2.70	^{13}C -NMR spectrum of compound 136	309
Figure 2.71	^1H - ^1H COSY spectrum of compound 136	310
Figure 2.72	HSQC spectrum of compound 136	310
Figure 2.73	HMBC spectrum of compound 136	311
Figure 2.74	Expansion of HMBC spectrum of compound 136	311
Figure 2.75	^1H -NMR spectrum of compound 137a and 137b	312
Figure 2.76	^{13}C -NMR spectrum of compound 137a and 137b	312
Figure 2.77	COSY spectrum of compound 137a and 137b	313
Figure 2.78	HSQC spectrum of compound 137a and 137b	313
Figure 2.79	HMBC spectrum of compound 137a and 137b	314

Figure 2.80	Expansion of HMBC spectrum of compound 137a and 137b	314
Figure 2.81	¹ H-NMR spectrum of compound 138	315
Figure 2.82	¹³ C-NMR spectrum of compound 138	315
Figure 2.83	¹ H-NMR spectrum of compound 139	316
Figure 2.84	¹³ C-NMR spectrum of compound 139	316
Figure 2.85	¹ H-NMR spectrum of compound 140	317
Figure 2.86	¹³ C-NMR spectrum of compound 140	317
Figure 2.87	¹ H-NMR spectrum of compound 142	318
Figure 2.88	¹ H-NMR spectrum of compound 142	318
Figure 2.89	¹³ C-NMR spectrum of compound 142	319
Figure 2.90	¹ H-NMR spectrum of compound 143	320
Figure 2.91	¹³ C-NMR spectrum of compound 143	320
Figure 2.92	¹ H-NMR spectrum of compound 146	321
Figure 2.93	¹³ C-NMR spectrum of compound 146	321
Figure 2.94	¹ H-NMR spectrum of compound 148	322
Figure 2.95	¹³ C-NMR spectrum of compound 148	322

LIST OF TABLES

CHAPTER I		PAGE
Table 1.1	Enzyme inhibition of (+)-pochonicine and (-)-pochonicine	11
Table 1.2	Summary of enzyme inhibition carried out by Yu and coworkers	23
Table 1.3	Glycosidase inhibition studies	38
CHAPTER II		
Table 2.1	Glycosidase inhibition studies.	224
Table 2.2	Crystal data and structure refinement parameters for 107.HCl	275
Table 2.3	Crystal data and structure refinement parameters for 136.	276

GENERAL EXPERIMENTAL CONSIDERATIONS

All solvents employed were purified by standard procedures. Anhydrous solvents were dried over sodium wire (THF, diethyl ether, benzene) or molecular sieves (CH₂Cl₂, CHCl₃, DMF).

Nitrogen or Argon gas used for creating inert atmosphere was freed from oxygen prior to entry into reaction vessel.

Commercially sourced TLC plates were used, and the spots were visualized by exposure to iodine, or by dipping in KMnO₄ and ninhydrin solution. Column chromatography was carried out on silica gel (230–400 mesh) using mixtures of hexane and ethyl acetate as eluent unless otherwise mentioned.

Optical rotations were recorded on an Autopol V (Rudolph Research Flanders, NJ) instrument. All the rotations were measured at 589 nm (sodium D' line).

All melting points reported in this thesis are uncorrected and were taken on an electric melting point apparatus (Ambassador, India).

Freeze-drying of samples was done on a Freezone 2.5 (Labconco, USA) lyophilizer.

Inhibition studies were carried out on Biotek Synergy 2 microplate reader.

IR spectra were taken within the range 4000–600 cm⁻¹ either as KBr pellets or neat on a Nicolet (Madison, USA) FT-IR spectrophotometer (Model Protégé 460).

¹H-NMR spectra were recorded on a 300 MHz or 400 MHz Bruker Spectrospin DPX FT-NMR instruments. The solvents employed were CDCl₃, CD₃OD, D₂O or DMSO-*d*₆ with Me₄Si as the internal standard. The multiplicities are denoted as s-singlet, br s-broad singlet, d-doublet, br m-broad multiplet, t-triplet, q-quartet, dt-doublet triplet and m-multiplet. ¹³C-

NMR spectra were recorded at 75 MHz or at 100 MHz instrument. The chemical shifts are reported in δ values (parts per million, ppm) relative to the internal standard Me₄Si.

High-resolution mass spectra were recorded with a Q-TOF Bruker instrument, using electrospray ionization (ESI) as the ionization method.

X-ray crystallography

Suitable crystal of compounds, were obtained by slow evaporation of their saturated solutions in chloroform-methanol solvent mixture or water. BRUKER AXS SMART-APEX diffractometer equipped with CCD area detector ($K\alpha=0.71073\text{\AA}$, monochromator: graphite). Frames were collected at T=298K by ω , ϕ and 2θ -rotation with full quadrant data collection strategy (four domains each with 600 frames) at 10s per frame with SMART. The measured intensities were reduced to F^2 and corrected for absorption with SAINT. Structure solution and refinement were carried out with the SHELXTL package by direct methods. Non-hydrogen atoms were refined anisotropically. All hydrogen atoms were included in idealized positions, and a riding model was used for the refinement. Images were created with the program Diamond.

COMMON ABBREVIATIONS

ent	:	Enantiomer
Cbz	:	Carbobenzyloxy
2,2-DMP	:	2,2-Dimethoxy propane
Boc	:	Tertiary-butoxycarbonyl
epi	:	Epimer
aq	:	Aqueous
Bn	:	Benzyl
Conc.	:	Concentrated
LDA	:	Lithium diisopropyl amide
<i>c</i>	:	Concentration
cat	:	Catalyst
COSY	:	Correlation Spectroscopy
HSQC	:	Heteronuclear Single Quantum Coherence
NOESY	:	Nuclear Overhauser Effect Spectroscopy
HMBC	:	Heteronuclear Multiple Bond Correlation
HETCOR	:	Heteronuclear Correlation
DCC	:	<i>N, N'</i> -dicyclohexylcarbodiimide
DCM	:	Dichloromethane
DEAD	:	Diethyl azodicarboxylate
DMAP	:	4-dimethylaminopyridine
DMF	:	<i>N, N'</i> -dimethylformamide
DMSO	:	Dimethylsulfoxide
ppm	:	Parts per million
dr	:	Diastereomeric ratio
DEPT	:	Distortionless Enhancement by Polarization Transfer
equiv	:	Equivalent
ESI	:	Electrospray ionization
CSA	:	Camphor sulphonic acid
g	:	Gram
GalNAcase	:	<i>N</i> -acetyl- α -D-galactosaminidase
h	:	Hour
HRMS	:	High Resolution Mass Spectrometry

Hz	:	Hertz
IC ₅₀	:	Half maximal Inhibitory Concentration
ⁱ Pr	:	Isopropyl
IR	:	Infrared
K _i	:	Inhibition Constant
LAH	:	Lithium Aluminum Hydride
Me	:	Methyl
mg	:	Milligrams
min	:	Minute
mL	:	Milliliters
mM	:	Millimolar
mmol	:	Millimoles
μM	:	Micromolar
M.p.	:	Melting Point
Ms	:	Mesyl
MS	:	Molecular sieves
MHz	:	Megahertz
m/z	:	mass-to-charge ratio
NBS	:	<i>N</i> -Bromosuccinimide
NIS	:	<i>N</i> -Iodosuccinimide
nM	:	Nanomolar
NMO	:	<i>N</i> -Methylmorpholine <i>N</i> -oxide
NMR	:	Nuclear magnetic resonance
Nu	:	Nucleophile
Pd/C	:	Palladium on activated carbon
Ph	:	Phenyl
<i>p</i> -TSA	:	Para-toluenesulfonic acid
TsCl	:	Para-toluenesulfonyl chloride
Ts	:	Para-toluenesulfonyl
R _f	:	Retention factor
ref	:	Reference
rt	:	Room temperature
TBAF	:	Tertiary-butyldimethyl silyl fluoride

TBS	:	Tertiary-butyldimethyl silyl
TBSCl	:	Tertiary-butyldimethyl silyl chloride
TBSOTf	:	Tertiary-butyldimethyl silyl triflate
TBDPS	:	Tertiary-butyl diphenyl silyl
TMSCN	:	Trimethyl silyl cyanide
THF	:	Tetrahydrofuran
TLC	:	Thin layer chromatography
TMS	:	Tetramethyl silane
liq	:	Liquid
DIPEA	:	Diisopropyl ethyl amine
Py	:	Pyridine
DNA	:	Deoxyribonucleic acid
RNA	:	Ribonucleic acid
ATP	:	Adenosine triphosphate
HIV	:	Human immunodeficiency virus
AIDS	:	Acquired immunodeficiency syndrome
US FDA	:	United states Food and Drug Administration
HBV	:	Hepatitis B virus
HCV	:	Hepatitis C virus
mRNA	:	Messenger Ribonucleic acid
AON	:	Antisense oligonucleotide
PNP	:	Purine nucleoside phosphorylase
Ipc	:	Diisopinocampyl
de	:	Diastereomeric excess
mCPBA	:	Meta chloro perbenzoic acid
TFA	:	Trifluoroacetic acid
Fmoc	:	Fluorenylmethyloxycarbonyl
DMTrCl	:	Dimethoxy trityl
CbzCl	:	Carboxybenzyl chloride
DAST	:	Diethylaminosulfur trifluoride
cAMP	:	Cyclic adenosine mono phosphate
cGMP	:	Cyclic guanosine mono phosphate
NAD ⁺	:	Nicotinamide adenine dinucleotide

NADP ⁺	:	Nicotinamide adenine dinucleotide phosphate
FAD	:	Flavin adenine dinucleotide
FMN	:	Flavin mono nucleotide
dGTP	:	Deoxy guanosine triphosphate